• 1
    Wilson PW, Garrison RJ, Castelli WP, Feinleib M, McNamara PM, Kannel WB. Prevalence of coronary heart disease in the Framingham Offspring Study: role of lipoprotein cholesterols. Am J Cardiol 1980; 46: 64954.
  • 2
    Wilson PW, D'Agostino RB, Levy D, Belanger AM, Silbershatz H, Kannel WB. Prediction of coronary heart disease using risk factor categories. Circulation 1998; 97: 183747.
  • 3
    Hamsten A, Iselius L, Dahlen G, de Faire U. Genetic and cultural inheritance of serum lipids, low and high density lipoprotein cholesterol and serum apolipoproteins A-I, A-II and B. Atherosclerosis 1986; 60: 199208.
  • 4
    Despres JP. Dyslipidaemia and obesity. Baillieres Clin Endocrinol Metab 1994; 8: 62960.
  • 5
    Marenberg ME, Risch N, Berkman LF, Floderus B, de Faire U. Genetic susceptibility to death from coronary heart disease in a study of twins. N Engl J Med 1994; 330: 104146.
  • 6
    Willson TM, Brown PJ, Sternbach DD, Henke BR. The PPARs: from orphan receptors to drug discovery. J Med Chem 2000; 43: 52750.
  • 7
    Leibowitz MD, Fievet C, Hennuyer N et al. Activation of PPARdelta alters lipid metabolism in db/db mice. FEBS Lett 2000; 473: 33336.
  • 8
    Oliver WR, Shenk JL, Snaith MR et al. A selective peroxisome proliferator-activated receptor delta agonist promotes reverse cholesterol transport. Proc Natl Acad Sci USA 2001; 98: 530611.
  • 9
    Skogsberg J, Kannisto K, Cassel TN, Hamsten A, Eriksson P, Ehrenborg E. Evidence that peroxisome proliferator-activated receptor delta influences cholesterol metabolism in men. Arterioscler Thromb Vasc Biol 2003; 23: 63743.
  • 10
    The West of Scotland Coronary Prevention Study Group. Screening experience and baseline characteristics in the West of Scotland Coronary Prevention Study. The WOSCOPS Study Group. West of Scotland Coronary Prevention Study. Am J Cardiol 1995; 76: 48591.
  • 11
    The West of Scotland Coronary Prevention Study Group. A coronary primary prevention study of Scottish men aged 45–64 years: trial design. The West of Scotland Coronary Prevention Study Group. J Clin Epidemiol 1992; 45: 84960.
  • 12
    Shepherd J, Cobbe SM, Ford I et al. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. West of Scotland Coronary Prevention Study Group. N Engl J Med 1995; 333: 130107.
  • 13
    Lipid Research Clinics Program. Lipid and Lipoprotein Analysis: Manual of Laboratory Operations (Publication NIH/75–628). Washington DC: Department of Health, Education and Welfare, 1982.
  • 14
    Whittington RB, Harkness J. Whole-blood viscosity, as determined by plasma viscosity, haematocrit, and shear. Biorheology 1982; 19: 17584.
  • 15
    Lowe G, Smith W, Tunstall-Pedoe H. Cardiovascular risk and haemorheology: results from the Scottish Heart Health Study and the MONICA-project, Glasgow. Clin Hemorheol 1988; 8: 51824.
  • 16
    Caslake MJ, Packard CJ, Suckling KE, Holmes SD, Chamberlain P, Macphee CH. Lipoprotein-associated phospholipase A(2), platelet-activating factor acetylhydrolase: a potential new risk factor for coronary artery disease. Atherosclerosis 2000; 150: 41319.
  • 17
    Yarnell JW, Baker IA, Sweetnam PM et al. Fibrinogen, viscosity, and white blood cell count are major risk factors for ischemic heart disease. The Caerphilly and Speedwell collaborative heart disease studies. Circulation 1991; 83: 83644.
  • 18
    Tai ES, Demissie S, Cupples LA et al. Association between the PPARA L162V polymorphism and plasma lipid levels: the Framingham Offspring Study. Arterioscler Thromb Vasc Biol 2002; 22: 80510.
  • 19
    Vohl MC, Lepage P, Gaudet D et al. Molecular scanning of the human PPARa gene: association of the L162v mutation with hyperapobetalipoproteinemia. J Lipid Res 2000; 41: 94552.
  • 20
    Flavell DM, Pineda Torra I, Jamshidi Y et al. Variation in the PPARalpha gene is associated with altered function in vitro and plasma lipid concentrations in Type II diabetic subjects. Diabetologia 2000; 43: 67380.
  • 21
    Jamshidi Y, Flavell DM, Hawe E, MacCallum PK, Meade TW, Humphries SE. Genetic determinants of the response to bezafibrate treatment in the lower extremity arterial disease event reduction (LEADER) trial. Atherosclerosis 2002; 163: 18392.
  • 22
    Fajas L, Schoonjans K, Gelman L et al. Regulation of peroxisome proliferator-activated receptor gamma expression by adipocyte differentiation and determination factor 1/sterol regulatory element binding protein 1: implications for adipocyte differentiation and metabolism. Mol Cell Biol 1999; 19: 5495503.
  • 23
    Kim JB, Wright HM, Wright M, Spiegelman BM. ADD1/SREBP1 activates PPARgamma through the production of endogenous ligand. Proc Natl Acad Sci USA 1998; 95: 433337.
  • 24
    Martin G, Duez H, Blanquart C et al. Statin-induced inhibition of the Rho-signaling pathway activates PPARalpha and induces HDL apoA-I. J Clin Invest 2001; 107: 142332.
  • 25
    Chinetti G, Fruchart JC, Staels B. Peroxisome proliferator-activated receptors (PPARs): nuclear receptors at the crossroads between lipid metabolism and inflammation. Inflamm Res 2000; 49: 497505.
  • 26
    Devchand PR, Keller H, Peters JM, Vazquez M, Gonzalez FJ, Wahli W. The PPARalpha-leukotriene B4 pathway to inflammation control [see comments]. Nature 1996; 384: 3943.
  • 27
    Ricote M, Li AC, Willson TM, Kelly CJ, Glass CK. The peroxisome proliferator-activated receptor-gamma is a negative regulator of macrophage activation. Nature 1998; 391: 7982.
  • 28
    Straus DS, Pascual G, Li M et al. 15-deoxy-delta 12,14-prostaglandin J2 inhibits multiple steps in the NF-kappa B signaling pathway. Proc Natl Acad Sci USA 2000; 97: 484449.
  • 29
    Packard CJ, O'Reilly DS, Caslake MJ et al. Lipoprotein-associated phospholipase A2 as an independent predictor of coronary heart disease. West of Scotland Coronary Prevention Study Group. N Engl J Med 2000; 343: 114855.
  • 30
    Peters JM, Lee SS, Li W et al. Growth, adipose, brain, and skin alterations resulting from targeted disruption of the mouse peroxisome proliferator-activated receptor beta(delta). Mol Cell Biol 2000; 20: 511928.